|
| Index | - | P/E | - | EPS (ttm) | -20.30 | Insider Own | 27.90% | Shs Outstand | 22.82M | Perf Week | -45.90% |
| Market Cap | 79.87M | Forward P/E | - | EPS next Y | -1.17 | Insider Trans | 0.05% | Shs Float | 13.39M | Perf Month | -36.01% |
| Income | - | PEG | - | EPS next Q | -0.20 | Inst Own | 0.30% | Short Float | 0.17% | Perf Quarter | -71.22% |
| Sales | - | P/S | - | EPS this Y | -37.80% | Inst Trans | - | Short Ratio | 0.29 | Perf Half Y | - |
| Book/sh | -140.80 | P/B | - | EPS next Y | 28.70% | ROA | - | Target Price | 24.50 | Perf Year | - |
| Cash/sh | 0.36 | P/C | 9.62 | EPS next 5Y | - | ROE | - | 52W Range | 3.99 - 13.80 | Perf YTD | -44.62% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -74.64% | Beta | - |
| Dividend % | - | Quick Ratio | 2.30 | Sales past 5Y | - | Gross Margin | - | 52W Low | -12.28% | ATR | 0.78 |
| Employees | 15 | Current Ratio | 2.30 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 26.81 | Volatility | 18.78% 12.91% |
| Optionable | No | Debt/Eq | - | EPS Q/Q | -32.70% | Profit Margin | - | Rel Volume | 1.83 | Prev Close | 4.14 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 80.03K | Price | 3.50 |
| Recom | 1.50 | SMA20 | -41.88% | SMA50 | -54.61% | SMA200 | -61.43% | Volume | 146,479 | Change | -15.46% |
 | ||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
| Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York. | ||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite